Neurological Disorder Clinical Trial
— MINDSOfficial title:
Multidisciplinary Lifestyle Interventions for Neurological Disorders During the Silent Phase (MINDS)
NCT number | NCT05984056 |
Other study ID # | 22-941 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 13, 2023 |
Est. completion date | June 2024 |
This clinical trial aims to test the impact of multidisciplinary lifestyle interventions (MLI) in neurologically healthy but at-risk individuals. It aims to find out: - if giving four different kinds of lifestyle intervention and education slows down or reverses the expression of neurological disorder or their biomarkers. - new biomarkers that either help in the early detection of neurological disease or identify the impact of various lifestyle interventions combined. Participants will be randomized to the intervention or observation arm. Various biological samples and tests, along with survey questionnaires, will be performed at the time of entering the study, at 12 weeks after enrollment, and then at the end of the study at 12 months. - Intervention arm: Participants will receive weekly, instructor-led intervention sessions (virtual group sessions) for 12 weeks. After the 12-week mark, participants will be encouraged to practice what they learned for nine more months. - Observation arm: The intervention group will be compared to another group that did not get the intervention
Status | Recruiting |
Enrollment | 200 |
Est. completion date | June 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: 1. Participants must be enrolled in Cleveland Clinic Brain Study (CCBS). CCBS is a prospective non-interventional study platform for the hyper characterization of the brain and body systems changes (blood, cardio-vascular, voice, visual, cognitive, digestive, brain structure, and neurophysiology) in neurologically healthy individuals 50 years and older. All individuals undergo periodic and thorough neurological assessments, blood tests, and cardiac, neurocognitive, imaging, vision, and neurophysiological testing. 2. CCBS participants who do not have a clinical neurological disease (except headache) but show signs of being at risk of developing one of the four conditions based on the below criteria: - Stroke: MRI changes consistent with moderate-severe white matter disease on Fazekas Scale - Epilepsy: Spikes/Poylspikes/ Sharp Waves on EEG - Movement Disorder: Hyposmia on U. Penn Smell Identification Test (UPSIT <10 percentile based on age) - Dementia: Auditory Verbal Learning Test (AVLT) Trial 1-5 total or Trial 7 scoring <=1.5 SD and subjective memory on BACH score (proprietary test) 0-40 Exclusion Criteria: 1. Participants who are actively (at the time of enrollment) engaged in 2 or more of the study interventions. 2. Participants with a diagnosed, symptomatic, chronic illness (i.e., significant psychiatric concerns, liver, gastrointestinal, respiratory, renal, cardiac, etc.) who, based on primary investigator review, cannot safely or effectively participate in the study. 3. Participants undergoing intensive medical treatment for serious or life-threatening illness (e.g., chemotherapy, etc.) that, in an investigator's opinion, would impact study participation. 4. Participants who are currently pregnant or less than six weeks postpartum 5. Participants with significant hearing loss 6. Participants with severe impairment of vision/ blindness 7. Participants who require a legally authorized representative (LAR) or lack the capacity to consent for themselves |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Vineet Punia MD | Ohio Department of higher education |
United States,
Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Bories L, Cufi MN, Dantoine T, Dartigues JF, Desclaux F, Gabelle A, Gasnier Y, Pesce A, Sudres K, Touchon J, Robert P, Rouaud O, Legrand P, Payoux P, Caubere JP, Weiner M, Carrie I, Ousset PJ, Vellas B; MAPT Study Group. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017 May;16(5):377-389. doi: 10.1016/S1474-4422(17)30040-6. Epub 2017 Mar 27. — View Citation
Dhana K, James BD, Agarwal P, Aggarwal NT, Cherian LJ, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. MIND Diet, Common Brain Pathologies, and Cognition in Community-Dwelling Older Adults. J Alzheimers Dis. 2021;83(2):683-692. doi: 10.3233/JAD-210107. — View Citation
Jin B, Krishnan B, Adler S, Wagstyl K, Hu W, Jones S, Najm I, Alexopoulos A, Zhang K, Zhang J, Ding M, Wang S; Pediatric Imaging, Neurocognition, and Genetics Study; Wang ZI. Automated detection of focal cortical dysplasia type II with surface-based magnetic resonance imaging postprocessing and machine learning. Epilepsia. 2018 May;59(5):982-992. doi: 10.1111/epi.14064. Epub 2018 Apr 10. — View Citation
Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018 Nov;14(11):653-666. doi: 10.1038/s41582-018-0070-3. — View Citation
Marcason W. What Are the Components to the MIND Diet? J Acad Nutr Diet. 2015 Oct;115(10):1744. doi: 10.1016/j.jand.2015.08.002. No abstract available. — View Citation
Moll van Charante EP, Richard E, Eurelings LS, van Dalen JW, Ligthart SA, van Bussel EF, Hoevenaar-Blom MP, Vermeulen M, van Gool WA. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016 Aug 20;388(10046):797-805. doi: 10.1016/S0140-6736(16)30950-3. Epub 2016 Jul 26. — View Citation
Morris MC, Tangney CC, Wang Y, Sacks FM, Barnes LL, Bennett DA, Aggarwal NT. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015 Sep;11(9):1015-22. doi: 10.1016/j.jalz.2015.04.011. Epub 2015 Jun 15. — View Citation
Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12. — View Citation
Panda A, Mehta BB, Coppo S, Jiang Y, Ma D, Seiberlich N, Griswold MA, Gulani V. Magnetic Resonance Fingerprinting-An Overview. Curr Opin Biomed Eng. 2017 Sep;3:56-66. doi: 10.1016/j.cobme.2017.11.001. — View Citation
Wik L, Nordberg N, Broberg J, Bjorkesten J, Assarsson E, Henriksson S, Grundberg I, Pettersson E, Westerberg C, Liljeroth E, Falck A, Lundberg M. Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide Analysis. Mol Cell Proteomics. 2021;20:100168. doi: 10.1016/j.mcpro.2021.100168. Epub 2021 Oct 27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathology progression | At the time of study completion, a participant will be considered to show "Pathology progression" if they fulfill either of the two conditions:
Clinically diagnosed with any of the above four conditions Show the following changes compared to the baseline: Stroke: Asymptomatic cortical infarct or further increase in white matter disease MRI changes Epilepsy: Increase in burden (per hour) of Spikes/Sharp Waves/Polyspikes or electrographic seizure on EEG Movement Disorder: >4 points increase on modified Unified Parkinson's Disease Rating Scale (UPDRS) administered remotely Dementia: Increase in number of domain testing = 1.5 SD or drop in scores < 2SD |
12 months | |
Secondary | Quality of Life in Neurological Disorders (Neuro QoL) | Neuro-QOL uses a 5-point scale for scoring items, with questions ranging from least (1) to most (5) Neuro-QOL uses a T score with a mean of 50 and SD of 10 High scores indicate worse or undesirable, self-reported health. | 12 months | |
Secondary | PHQ8 (Patient Health Questionnaire) | It is an eight-item questionnaire used to screen for and assess the severity of depression. The PHQ-8 total score ranges from 0 to 24. A score of 0 to 4 indicates no depression, 5 to 9 indicates mild depression, 10 to 14 indicates moderate depression, 15 to 19 indicates moderately severe depression and 20 or higher indicates severe depression. A score of 10 or greater is considered major depression, and 20 or more is severe major depression. | 12 months | |
Secondary | Generalized Anxiety Disorder Questionnaire-7 (GAD-7) | A screening instrument used to detect anxiety symptoms. The total score for the seven items in the GAD-7 ranges from 0 to 21. The scores are calculated by assigning scores of 0, 1, 2, and 3 to the response categories of "not at all," "several days," "more than half the days," and "nearly every day".
The scores are interpreted as follows: 0-4: Minimal anxiety 5-9: Mild anxiety 10-14: Moderate anxiety 15 or greater: Severe anxiety 6-10: Moderate 11-15: Moderately severe anxiety Scores above 10 are considered to be in the clinical range. |
12 months | |
Secondary | General Self-Efficacy Scale (GSE) | The GSE is a 10-item psychometric scale that assesses optimistic self-beliefs to cope with difficult demands in life (coping skills). The minimum score for GSE is 10, and the maximum is 40.
The higher the score, the greater the individual's generalized self-efficacy belief. |
12 months | |
Secondary | Perceived Stress Scale (PSS-10) | The Perceived Stress Scale (PSS) is a 10-item questionnaire that evaluates participants' self-reported amount of stress by assessing their thoughts and feelings in the previous month. Each question is scored from 0 (never) to 5 (very often), with a total possible score range of 0 to 40.
Higher scores indicate a higher level of stress. Here are some cut-off scores for the PSS: 0-13: low stress 14-26: moderate stress 27-40: high perceived stress 14 and 27: cut-off scores for moderate and high perceived stress, respectively The estimated minimal clinically important difference for the PSS-10 is 11 points |
12 months | |
Secondary | Patient-Reported Outcomes Measurement Information System (PROMIS) | PROMIS is a system of measures that evaluates and monitors adults' physical, mental, and social health.
PROMIS scores range from 36.3 to 82.7, with higher scores indicating worse outcome. |
12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06390800 -
Personalized Motor Learning in Primary Care Physiotherapy (TREAT)
|
||
Not yet recruiting |
NCT04386525 -
Omega 3 and Ischemic Stroke; Fish Oil as an Option
|
Phase 4 | |
Completed |
NCT06278025 -
Dysphagia and Deep Cervical Flexor Muscles
|
||
Completed |
NCT03300856 -
Chart Review: Central Motor Conduction Time in Neurological Disorders
|
||
Recruiting |
NCT06219200 -
Automatic Voice Analysis for Dysphagia Screening in Neurological Patients
|
||
Recruiting |
NCT05106725 -
Wearable Devices and Biomarkers Project (Healthiomics)
|
||
Completed |
NCT04119297 -
Effects of Cold Application and Heparinoid on Periorbital Edema and Ecchymosis
|
N/A | |
Completed |
NCT03490539 -
Disease-Modifying Treatments for Myasthenia Gravis
|
||
Recruiting |
NCT05425186 -
A Reliability and Validity Study: Urdu Version of Rivermead Extended Activities of Daily Life
|
||
Completed |
NCT03890965 -
Effects of the Application of a Reflex Locomotion Program in the Neurological Hand
|
N/A | |
Not yet recruiting |
NCT05363085 -
The Cerebral-Respiratory Interaction in Controlled Mechanically Ventilated Neurosurgical Patients. (The CeRes-CMV Study)
|
||
Recruiting |
NCT03699514 -
Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology
|
||
Completed |
NCT04820153 -
Monitoring Physical Activity in Hispanic Women With Chronic Neurological Disorders
|
N/A | |
Completed |
NCT03639909 -
Analysis of the Sweat Response According to the Pathology in Neurologic Patients
|
||
Completed |
NCT05350839 -
Reliability and Validity of HHIRS General Quality of Life Questionnaire
|
||
Completed |
NCT04934085 -
COVID-19 Versus Neurological Impairment, Physical Activity, Social Contacts and Education
|
||
Recruiting |
NCT06072287 -
The Living With a Long-Term Condition Study
|
||
Recruiting |
NCT04436068 -
Hyperfine Portable MRI in Hydrocephalus and Other Conditions Prompting Outpatient Brain Imaging
|
N/A | |
Completed |
NCT04259151 -
Evaluation on Standardized Circuits of the Interest of a Robotic Module of Assistance to the Driving
|
N/A | |
Completed |
NCT03606668 -
Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders
|
N/A |